Results from the EMPA-REG OUTCOME trial and the pooled CANVAS/CANVAS-R programme have raised a strong hypothesis that SGLT-2 inhibition could reduce the risk of kidney disease progression in CKD. Here, SLC5A2 is linked to chronic kidney disease.